Review

Anti-Inflammatory and/or Anti-Fibrotic Treatment of MPO-ANCA-Positive Interstitial Lung Disease: A Short Review

Hideaki Yamakawa 1,2,*, Yuko Toyoda 3, Tomohisa Baba 4, Tomoo Kishaba 5, Taiki Fukuda 6, Tamiko Takemura 7 and Kazuyoshi Kuwano 2

1 Department of Respiratory Medicine, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama 330-8553, Japan
2 Department of Respiratory Medicine, Tokyo Jikei University Hospital, 3-25-8 Nishi-shinbashii, Minato-ku, Tokyo 105-8461, Japan; kkuwano@jikei.ac.jp
3 Department of Internal Medicine, Japanese Red Cross Kochi Hospital, 1-4-63-11 Hadaminamimachi, Kochi 780-8562, Japan; yuyutoyo@gmail.com
4 Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-ku, Yokohama 236-0051, Japan; baba@kanagawa-junko.jp
5 Department of Respiratory Medicine, Okinawa Chubu Hospital, Okinawa, 81 Miyazato, Uruma 904-2293, Japan; kishabatomoo@gmail.com
6 Department of Radiology, The Jikei University Daisan Hospital, 4-11-1 Izumihoncho Komae-shi, Tokyo 201-8601, Japan; taiki.fukuda@gmail.com
7 Department of Pathology, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-ku, Yokohama 236-0051, Japan; tamikobyori@gmail.com

* Correspondence: hide1144@jikei.ac.jp

Abstract: The presence of a lung lesion is common in microscopic polyangiitis (MPA), and interstitial lung disease (ILD) can lead to a poor prognosis. Although myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) are often present in patients with MPA, patients with ILD and MPO-ANCA positivity but without other manifestations of systemic vasculitis have also been reported. Therefore, the possible association between MPO-ANCA, MPA, and idiopathic ILD remains unclear. This problematic matter has influenced the treatment strategy of MPO-ANCA-positive ILD patients without systemic vasculitis. Clinicians should undertake treatment with careful consideration of the four major causes of death in MPO-ANCA-positive ILD: acute exacerbation of ILD, progressive lung fibrosis, infectious comorbidities, and diffuse alveolar hemorrhage. Further, clinicians need to carefully judge whether inflammation or fibrosis is the dominant condition with reference to the patient’s clinical domain and radiopathological lung features. Recently, anti-fibrotic agents such as nintedanib and pirfenidone were shown to be effective in treating various etiologies associated with ILD and have thus led to the widening of treatment options. In this review, the clinical characteristics, radiopathology, prognosis, and therapeutic options in patients with MPO-ANCA-positive ILD are summarized using limited information from previous studies.

Keywords: microscopic polyangiitis; interstitial lung disease; myeloperoxidase antineutrophil cytoplasmic antibody; therapeutic option

1. Introduction

Antineutrophil cytoplasmic antibodies (ANCA) are generally detected in multisystemic diseases, namely ANCA-associated vasculitides such as microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA) [1–3]. The presence of a lung lesion is a common and important clinical feature in ANCA-associated vasculitides [2,4]. However, interstitial lung disease (ILD) is rarely seen in patients with GPA and EGPA [1–4], but the presence of ILD is a common and important clinical feature in MPA [1,3,4]. In addition, MPO-ANCA have been frequently identified in patients with ILD without multisystemic disease. A recent report showed...
that ILD was diagnosed before (52%) or simultaneously (39%) with ANCA-associated vasculitides [5]. Therefore, its association with ILD has often been discussed [6–8] because ILD can lead to a poor prognosis in patients with MPA [5,9–11]. In addition, patients with pulmonary fibrosis and ANCA positivity but without other manifestations of systemic vasculitis have also been reported, which was sometimes diagnosed as “pulmonary-limited type of ANCA-associated vasculitis” [8,12]. Furthermore, ANCA-positive conversion has been described in patients with an initial diagnosis of idiopathic ILD, with manifestations of systemic vasculitis occurring in some patients [13,14]. However, it is unclear whether ILD observed in the presence of only MPO-ANCA differs from idiopathic ILD and ILD with overt MPA [14]. Needless to say, this problematic matter has influenced the treatment strategy of MPO-ANCA-positive ILD patients without systemic vasculitis as a form of idiopathic ILD. Therefore, the aim of the present review was to assess the characteristics of MPO-ANCA-positive ILD using limited information from previous studies in this field and then focus on the future treatment of MPO-ANCA-positive ILD.

2. Prevalence and Clinical Manifestations

The prevalence of MPO-ANCA positivity ranges from 1.7% to 22.2% in patients with idiopathic ILD [8,13,15,16]. From the viewpoint of MPA, the prevalence of ILD ranges from 2.7% to 47.4% in patients with MPA [8,17–25]. ILD is more frequently associated with MPO-ANCA positivity in Japanese patients than in Western patients [5,26]. MPO-ANCA-positive ILD is usually observed in patients older than 65 years old as idiopathic pulmonary fibrosis (IPF) [17].

Conversion to MPO-ANCA positivity occurs in patients initially diagnosed as having idiopathic ILD at a reported rate of prevalence of 3.3% to 5.7% [13,15]. Moreover, a quarter of the patients with MPO-ANCA positivity at the diagnosis of idiopathic ILD or with conversion to MPO-ANCA positivity during follow-up developed MPA [8,13,15]. To put it differently, clinicians should be careful to note that MPA develops at a certain incidence rate in MPO-ANCA-positive ILD patients [8,10,13,15].

3. Morphological Domain

3.1. Radiological Findings

In previous reports, radiological analysis, especially by high-resolution computed tomography (HRCT), was used for the classification of patterns [27,28] in patients with MPO-ANCA-positive ILD. In patients with MPA, the most frequently occurring pattern was usual interstitial pneumonia (UIP) (50–78%), followed by nonspecific interstitial pneumonia (NSIP) (7–58%) and others (13–31%) [14,29–32]. MPO-ANCA-positive ILD without systemic vasculitis (i.e., idiopathic ILD) also showed a similar tendency (UIP: 12.9–53.9%, non-UIP: 13.6–58.1%) [31,32]. Honeycombing was seen in about 30% of the MPO-ANCA-positive ILD patients regardless of whether they had MPA-ILD or idiopathic ILD [30–32].

3.2. Pathological Findings

In studies that specifically described the characteristics of patients with ILD associated with MPA and MPO-ANCA-positive idiopathic ILD, UIP was the most frequent pathological pattern (46–100%), and marked dense fibrosis and areas of honeycombing were common in these specimens [17,20,21,33–35]. In addition, a high incidence of findings such as lymphoid hyperplasia, organizing pneumonia, pleuritis, and bronchiolitis is a characteristic observed in ILD associated with MPA and MPO-ANCA-positive idiopathic ILD [18,33,34].

3.3. Differences between MPO-ANCA-Positive ILD and UIP/IPF

For the reason stated above in regard to radiopathological findings, similar to UIP/IPF, MPO-ANCA-positive ILD most commonly showed a UIP pattern and honeycombing as rheumatoid arthritis (RA)-ILD [9,17,36], whereas ILD in patients with systemic sclerosis and myositis is predominantly associated with a non-UIP pattern [9,17,37]. A recent study
reported that the single nucleotide polymorphism (SNP) rs35705950T was more strongly associated with UIP than with non-UIP [38]. The SNP rs35705950 (G/T) in the promoter region of MUC5B, which encodes mucin 5B, is a strong genetic factor for UIP/IPF and RA-UIP [39,40]. The MUC5B promoter variant rs35705950 might also be a strong risk factor for MPA-ILD [41]. Therefore, these findings suggest at least a partially shared genetic susceptibility between MPO-ANCA-positive ILD and UIP/IPF.

However, some previous studies reported that MPO-ANCA-positive ILD (including MPA-ILD) and UIP/IPF showed different radiopathological features, despite having the same basic UIP pattern [30,31,33–35]. Radiologically, increased attenuation around areas of honeycombing and traction bronchiectasis (Figure 1A) was more frequently seen in MPO-ANCA-positive ILD than in UIP/IPF [30,31,34]. We reported that an anterior upper lobe honeycomb-like lesion, which represents a concentration of cystic air spaces within the anterior aspect of the upper lobes (Figure 1B), might be found with higher frequency in MPO-ANCA-positive ILD and RA-ILD than in other etiologies associated with ILD [31,42]. Pathologically, MPO-ANCA-positive ILD even with a UIP pattern showed more prominent inflammatory cell infiltration and cellular bronchiolitis, unlike UIP/IPF (Figure 2A–E) [8,14,17,33–35]. In other words, these pathological features correspond well to the presence of a radiological feature such as increased attenuation around areas of honeycombing and traction bronchiectasis [30,31,34]. Therefore, these features may be associated with a better response to anti-inflammatory therapies in MPO-ANCA-positive ILD patients, and clinicians should be careful to note the development of MPA in patients having these features [31,34] (Table 1).

| Age                                      | Commonly older than 65 years old (patients younger than 50 years old are rare) |
|------------------------------------------|--------------------------------------------------------------------------------|
| Smoking                                  | The majority of patients have a history of past cigarette smoking              |
| Sex                                      | Male (45.2–66.7%) ≒ Female (33.3–54.7%)                                      |
| HRCT findings                            | Framework: Subpleural and basal predominant distribution is often heterogeneous |
|                                          | Increased attenuation around honeycombing and traction bronchiectasis (19–39%) |
| Pathological findings                    | Framework: Dense fibrosis with architectural distortion, predominant subpleural and/or paraseptal distribution of fibrosis |
|                                          | More prominent inflammatory cell infiltration and cellular bronchiolitis compared with IPF |

Figure 1. (A) High-resolution computed tomography (HRCT) scan shows increased attenuation around honeycombing and traction bronchiectasis (dashed circle). (B) HRCT shows anterior upper lobe honeycomb-like lesion as a concentration of cystic air spaces within the anterior aspect of the upper lobes (black arrows).

Table 1. Characteristics and HRCT/pathological findings in MPO-ANCA-positive ILD and IPF.
4. Prognosis and Causes of Death

Studies of previous cohorts of patients with MPA-ILD reported median survival times of 4.1–11 years and 5-year survival rates of 46–60%, although long-term outcomes are less well reported [10,31,32,34,43]. In MPO-ANCA-positive ILD without systemic vasculitis as a form of idiopathic ILD, whether there is a difference in survival time and prognosis between patients with MPA-ILD and those with idiopathic ILD is currently controversial [31,32]. As a caveat, there is a high probability that patients with MPO-ANCA-positive ILD even if showing a UIP pattern that had longer survival than those with UIP/IPF [10,13,34]. The poor prognostic factors reported included older age, higher ANCA titers, higher levels of inflammatory markers (i.e., erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]), lower forced vital capacity, and anterior upper lobe honeycomb-like lesions [10,13,14,16,31,32,34,44].

The major causes of death in patients with MPO-ANCA-positive ILD were acute exacerbation (AE) of ILD (10–25.5%), chronic progressive fibrosing ILD (PF-ILD) (7.8–19%), infectious disease (19.2–20%), and diffuse alveolar hemorrhage (DAH) (4.3–30%) [10,11,31]. As a cautionary point, it is possible that patients with MPO-ANCA-positive idiopathic ILD may present with DAH as the initial manifestation of MPA development, which is a serious condition, as DAH can be life threatening [10,13,15,31]. Taken together, these findings suggest that clinicians should create a decision-making strategy for the treatment
of MPO-ANCA-positive ILD with an awareness of the presence of these four major causes of death (i.e., AE of ILD, PF-ILD, infectious disease, and DAH).

5. Therapeutic Assessment of MPO-ANCA-Positive ILD

5.1. ILD Patients with MPA

When ILD associated with MPA is diagnosed, treatment should be based on organ involvements of vasculitis [8]. Treatment of patients with MPA should include induction therapy using highly potent anti-inflammatory agents (e.g., corticosteroid, cyclophosphamide, rituximab, mycophenolate, and azathioprine) [9,14,17,32,44]. However, no studies have shown whether therapy to treat MPA itself is also effective on ILD. Unfortunately, ILD often independently leads to progressive lung fibrosis [45].

5.2. MPO-ANCA-Positive ILD Patients without Systemic Vasculitis as Idiopathic ILD

Initially, when MPO-ANCA-positive ILD without systemic vasculitis is considered, clinicians should determine whether the patient has a UIP pattern on HRCT. In patients with NSIP or an organizing pneumonia pattern, anti-inflammatory agents (mainly as corticosteroids) should be started to treat these conditions as idiopathic ILD [14,17].

Second, the therapeutic assessment of MPO-ANCA-positive ILD with a UIP pattern is most difficult and controversial due to the lack of evidence [14]. This also includes progressive pulmonary fibrosis (i.e., PF-ILD) with MPA despite anti-inflammatory therapies directed at treating MPA itself. Two main factors are important when considering the decision to start or switch treatment, whether inflammatory change or fibrotic change in ILD is the dominant factor [46].

One factor favoring inflammatory change is the presence of MPA-like disease (mock MPA), as indicated by recurrent unexplained fever and/or higher CRP/ESR and an upward trend in the MPO-ANCA titer. Moreover, the second factor is increased attenuation around fibrotic change seen on HRCT and prominent inflammatory cell infiltration in pathological lung lesions [1–3,47,48]. Regarding the former (i.e., mock MPA), if patients with MPO-ANCA-positive idiopathic ILD develop MPA, they should be treated with anti-inflammatory therapy because untreated MPA (particularly that with DAH) is normally progressive and fatal [13,31]. In terms of the latter as a radiopathological finding, anti-inflammatory therapy can be an effective course of treatment even if a UIP pattern is present, as shown in Figures 3 and 4. Therefore, if these conditions are present, anti-inflammatory therapy should be considered.

![Figure 3. High-resolution computed tomographic images of a patient with a stable course of MPA-ILD with UIP pattern for less than 3 years. The patient received anti-inflammatory therapies, after which wall thickening in the areas of honeycombing had improved, and the fibrotic lesion did not extend without requiring administration of an anti-fibrotic agent.](image-url)
which makes up the framework of the UIP pattern (Figure 3, same patient as in Figure 2). At the time of transbronchial lung cryobiopsy, high-resolution computed tomographic (HRCT) imaging showed subpleural reticulations with traction bronchiectasis as the framework of UIP and ground-glass opacities (GGOs) to some extent in the bilateral lung field. (B) At six months later, HRCT showed a moderate increase in disease extent of the reticulations and traction bronchiectasis as indications of progressive fibrosis, for which therapy with the anti-fibrotic agent nintedanib was initiated. (C) Elastica van Gieson staining.

Additionally, considering therapeutic assessment from a different perspective, anti-inflammatory therapy could be harmful in some cases. The importance of separating IPF from ILD associated with specific systemic conditions such as those related to connective tissue diseases has been emphasized [33,66]. It is recommended that IPF patients should not be treated with anti-inflammatory therapies [66,67]. A recent report also showed anti-inflammatory therapy as indicated by steroid use to have a higher risk of developing PF-ILD in connective tissue disease-associated ILD [68]. In RA-ILD, prednisolone doses higher than 10 mg are associated with a higher risk of infectious comorbidity [69]. As also
with MPA-ILD in elderly patients, the administration of high-dose corticosteroid therapy is a significant risk factor for severe infection, which is a main cause of death [70]. In general, corticosteroids had been considered to result in a higher risk of chronic pulmonary infection, such as nontuberculous mycobacteria and pulmonary aspergillosis [71,72]. Because the presence of emphysema may also be a risk factor for chronic pulmonary infection in ILD patients [73,74], when considering the initiation or strength of anti-inflammatory therapy, clinicians should pay particular attention to those patients having pulmonary emphysema with ILD to some extent. Moreover, Kawamura et al. reported that corticosteroid use was associated with an increased risk of AE of ILD even in a dose-dependent manner at low doses [75]. Although we cannot say for certain, incomplete anti-inflammatory therapy may cause harmful events such as infectious disease and AE of ILD that can lead to a poor prognosis. Taken together, when it is difficult to select between anti-inflammatory and anti-fibrotic therapy, anti-fibrotic therapy should be given priority in the patients at high risk for infection and AE of ILD such as initiation or long-term administration of moderate- to high-dose corticosteroid, concomitant to a certain extent with pulmonary emphysema (Figure 6).

Figure 6. Proposed protocol for the treatment of MPO-ANCA-positive ILD. MPA, microscopic polyangitis; MPO-ANCA, myeloperoxidase antineutrophil cytoplasmic antibody; ILD, interstitial lung disease; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; PF-ILD, progressive fibrosing ILD; HRCT, high-resolution computed tomography; UIP, usual interstitial pneumonia.

A prospective study should clarify the natural history of MPA-ILD and the role of ANCA positivity in patients with idiopathic ILD and offer a better therapeutic approach to treating the different groups of patients with this condition [76].

6. Conclusions

MPO-ANCA-positive ILD is not uncommon in any case of MPA-ILD or idiopathic ILD. Because some patients with MPO-ANCA positivity at the diagnosis of idiopathic ILD or with MPO-ANCA-positive conversion during follow-up develop MPA, clinicians should pay particular attention to the presence of DAH because this complication can be fatal.
In patients with MPA-ILD, MPA itself should first be stabilized with anti-inflammatory therapies. When MPO-ANCA-positive ILD with UIP pattern including PF-ILD with MPA is present despite anti-inflammatory therapies, clinicians need to carefully judge whether inflammation due to fibrosis is the dominant condition. When it is difficult to select between anti-inflammatory and anti-fibrotic therapy, anti-fibrotic therapy should be given priority in the patients at high risk for infection and AE of ILD. Because MPO-ANCA-positive ILD can result in the development of systemic vasculitides and/or a poor prognosis, the monitoring of patients over time is important. Multidisciplinary discussion among the pulmonologist, rheumatologist, radiologist, and pathologist can be useful to correctly approach the therapeutic assessment of patients with MPO-ANCA positivity.

Author Contributions: Conceptualization, H.Y., Y.T. and T.K.; methodology, T.B.; writing—original draft preparation, H.Y.; writing—review and editing, Y.T., T.B., T.K., T.F., T.T. and K.K.; supervision, K.K.; project administration, H.Y. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: H.Y., Y.T., T.K. and T.B. received honoraria from Nippon Boehringer Ingelheim Co., Ltd. T.F., T.T. and K.K. have no conflict of interest to declare.

References

1. Xiao, H.; Heeringa, P.; Hu, P.; Liu, Z.; Zhao, M.; Aratani, Y.; Maeda, N.; Falk, R.J.; Jennette, J.C. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 2002, 110, 955–963. [CrossRef]
2. Jennette, J.C.; Falk, R.J.; Bacon, P.A.; Basu, N.; Cid, M.C.; Ferrario, F.; Flores-Suarez, L.F.; Gross, W.L.; Guillemin, L.; Hagen, E.C.; et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheumatol. 2013, 65, 1–11. [CrossRef]
3. Kallenberg, C.G. The diagnosis and classification of microscopic polyangiitis. J. Autoimmun. 2014, 48–49, 90–93. [CrossRef]
4. Suppiah, R.; Robson, J.C.; Grayson, P.C.; Ponte, C.; Craven, A.; Khalid, S.; Judge, A.; Hutchings, A.; Merkel, P.A.; Luqmani, R.A.; et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann. Rheum. Dis. 2022, 81, 321–326. [CrossRef]
5. Maillet, T.; Goletto, T.; Beltramo, G.; Dupuy, H.; Jouneau, S.; Borie, R.; Crestani, B.; Cottin, V.; Blockmans, D.; Lazaro, E.; et al. Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor. J. Autoimmun. 2020, 106, 102338. [CrossRef]
6. Katsumata, Y.; Kawaguchi, Y.; Yamanaka, H. Interstitial lung disease with ANCA-associated vasculitis. Clin. Med. Insights Circ. Respir. Palm. Med. 2015, 9 (Suppl. 1), 51–56. [CrossRef]
7. Kishaba, T. Current perspective of progressive-fibrosing interstitial lung disease. Respir. Investig. 2022. [CrossRef] [PubMed]
8. Bando, M.; Homma, S.; Harigai, M. MPO-ANCA positive interstitial pneumonia: Current knowledge and future perspectives. Sarcoidosis Vasc. Diffus. Lung Dis. 2022, 38, e2021045. [CrossRef]
9. Kwon, M.; Lee, A.S.; Mira-Avendano, I.; Rojas, C.A.; Grage, R.; Abril, A. Interstitial lung disease in antineutrophil cytoplasmic antibody-associated vasculitis patients: Comparison with idiopathic pulmonary fibrosis. J. Clin. Rheumatol. 2021, 27, 324–330. [CrossRef]
10. Hozumi, H.; Kono, M.; Hasegawa, H.; Yasui, H.; Suzuki, Y.; Karayama, M.; Furuhashi, K.; Endomoto, N.; Fujisawa, T.; Inui, N.; et al. Clinical significance of interstitial lung disease and its acute exacerbation in microscopic polyangiitis. Chest 2021, 159, 2334–2345. [CrossRef]
11. Matsuda, S.; Kotani, T.; Suzuka, T.; Kiboshi, T.; Fukui, K.; Wakama, M.; Ishida, T.; Fujiki, Y.; Shiba, H.; Nagai, K.; et al. Evaluation of poor prognostic factors of respiratory related death in microscopic polyangiitis complicated by interstitial lung disease. Sci. Rep. 2021, 11, 1490. [CrossRef] [PubMed]
12. Ozaki, S.; Atsumi, T.; Hayashi, T.; Ishitani, M.; Kobayashi, S.; Kumagai, S.; Kurihara, Y.; Kurokawa, M.S.; Makino, H.; Nagafuchi, H.; et al. Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: The JMAAV study. Mod. Rheumatol. 2012, 22, 394–404. [CrossRef] [PubMed]
13. Kagiyama, N.; Takayanagi, N.; Kanauchi, T.; Ishiguro, T.; Yanagisawa, T.; Sugita, Y. Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis. BMJ Open Respir. Res. 2015, 2, e000058. [CrossRef] [PubMed]
37. Juge, P.A.; Lee, J.S.; Ebstein, E.; Furukawa, H.; Dobrinskikh, E.; Gazal, S.; Kannengiesser, C.; Ottaviani, S.; Oka, S.; Tohma, S.; et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N. Engl. J. Med. 2018, 379, 2209–2219. [CrossRef]
38. Putman, R.K.; Gudmundsson, G.; Araki, T.; Nishino, M.; Sigurdsson, S.; Gudmundsson, E.F.; Eiriksdottir, G.; Aspelund, T.; Ross, J.C.; San José Estépar, R.; et al. The MUC5B promoter polymorphism is associated with specific interstitial lung abnormality subtypes. Eur. Respir. J. 2017, 50, 1700537. [CrossRef]
39. Seibold, M.A.; Wise, A.L.; Speer, M.C.; Steele, M.P.; Brown, K.K.; Loyd, J.E.; Fingerlin, T.E.; Zhang, W.; Gudmundsson, G.; Groshong, S.D.; et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N. Engl. J. Med. 2011, 364, 1503–1512. [CrossRef]
40. Akiyama, M.; Kaneko, Y. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease. Autoimmun. Rev. 2022, 21, 103056. [CrossRef]
41. Namba, N.; Kawasaki, A.; Sada, K.E.; Hirano, F.; Kobayashi, S.; Yamada, H.; Furukawa, H.; Shimada, K.; Hashimoto, A.; Matsui, T.; et al. Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis. Ann. Rheum. Dis. 2019, 78, 1144–1146. [CrossRef] [PubMed]
42. Yamakawa, H.; Ogura, T.; Sato, S.; Nishizawa, T.; Kawabe, R.; Oba, T.; Kato, A.; Horikoshi, M.; Akasaka, K.; Amano, M.; et al. The potential utility of anterior upper lobe honeycomb-like lesion in interstitial lung disease associated with connective tissue disease. Respir. Med. 2020, 172, 106125. [CrossRef]
43. Hirayama, K.; Kobayashi, M.; Usui, J.; Arimura, Y.; Sugiyama, H.; Nitta, K.; Muso, E.; Wada, T.; Matsuo, S.; Yamagata, K. Pulmonary involvements of anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis in Japan. Nephrol. Dial. Transplant. 2015, 30 (Suppl. 1), 183–193. [CrossRef] [PubMed]
44. Foulon, G.; Delaval, P.; Valeyre, D.; Wallaert, B.; Debray, M.P.; Brauner, M.; Nicaise, P.; Cadranel, J.; Cottin, V.; Tazi, A.; et al. ANCA-associated lung fibrosis: Analysis of 17 patients. Respir. Med. 2008, 102, 1392–1398. [CrossRef]
45. Sebastiani, M.; Luppi, F.; Sambataro, G.; Castillo Villegas, D.; Cerri, S.; Tomietto, P.; Cassone, G.; Bocchino, M.; Atienza-Mateo, B.; Cameli, P.; et al. Interstitial lung disease and anti-myeloperoxidase antibodies: Not a simple association. J. Clin. Med. 2021, 10, 2548. [CrossRef]
46. Wijnsenbeek, M.; Cottin, V. Spectrum of fibrotic lung diseases. N. Engl. J. Med. 2020, 383, 958–968. [CrossRef]
47. Terrier, B.; Saadoun, D.; Sene, D.; Ghillani, P.; Amoura, Z.; Deray, G.; Fautrel, B.; Piette, J.C.; Cacoub, P. Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated renal vasculitides. Ann. Rheum. Dis. 2009, 68, 1564–1571. [CrossRef]
48. Kondoh, Y.; Makino, S.; Ogura, T.; Suda, T.; Tomioka, H.; Amano, H.; Anraku, M.; Enomoto, N.; Fujii, T.; Fujisawa, T.; et al. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respir. Investig. 2021, 59, 709–740. [CrossRef]
49. Ravaglia, C.; Wells, A.U.; Tomassetti, S.; Dubini, A.; Cavazza, A.; Picciucci, S.; Sverzellati, N.; Gurioli, C.; Gurioli, C.; Costabel, U.; et al. Transbronchial lung cryobiopsy in diffuse parenchymal lung disease: Comparison between biopsy from 1 segment and biopsy from 2 segments-diagnostic yield and complications. Respirration 2017, 93, 285–292. [CrossRef]
50. Enomoto, N.; Suda, T.; Kato, M.; Kaida, Y.; Nakamura, Y.; Imokawa, S.; Ida, M.; Chida, K. Quantitative analysis of fibroblastic foci in usual interstitial pneumonia. Respiration 2017, 93, 176. [CrossRef]
51. Elicker, B.M.; Kallianos, K.G.; Henry, T.S. The role of high-resolution computed tomography in the follow-up of diffuse lung disease. Eur. Respir. Rev. 2017, 26, 170008. [CrossRef] [PubMed]
52. Bulpa, P.A.; Dive, A.M.; Mertens, L.; Delos, M.A.; Jamart, J.; Evrand, P.A.; Gonzalez, M.R.; Installé, E.J. Combined bronchoalveolar lavage and transbronchial lung biopsy: Safety and yield in ventilated patients. Eur. Respir. J. 2003, 21, 489–494. [CrossRef] [PubMed]
53. Makino, S. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib. Mod. Rheumatol. 2021, 31, 13–19. [CrossRef] [PubMed]
54. Yamakawa, H.; Kitamura, H.; Takemura, T.; Ikeda, S.; Sekine, A.; Baba, T.; Iwasa, T.; Hagiwara, E.; Sato, S.; Ogura, T. Prognostic factors and disease behaviour of pathologically proven fibrotic non-specific interstitial pneumonia. Respirpirology 2018, 23, 1032–1040. [CrossRef] [PubMed]
55. Gibson, C.D.; Kugler, M.C.; Deshwal, H.; Munger, J.S.; Condos, R. Advances in targeted therapy for progressive fibrosing interstitial lung disease. Lung 2020, 198, 597–608. [CrossRef] [PubMed]
56. Silva, C.I.; Müller, N.L.; Hansell, D.M.; Lee, K.S.; Nicholson, A.G.; Wells, A.U. Nonspecific interstitial pneumonia and idiopathic pulmonary fibrosis: Changes in pattern and distribution of disease over time. Radiology 2008, 247, 251–259. [CrossRef]
57. Adegunsoye, A.; Oldham, J.M.; Bellam, S.K.; Montner, S.; Churpek, M.M.; Noth, I.; Vrij, R.; Strek, M.E.; Chung, J.H. Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases. Ann. Am. Thorac. Soc. 2019, 16, 580–588. [CrossRef]
58. Leuschner, G.; Behr, J. Acute exacerbation in interstitial lung disease. Front. Med. 2017, 4, 176. [CrossRef]
59. Suzuki, A.; Kondoh, Y.; Brown, K.K.; Johkoh, T.; Kataoka, K.; Fukuoaka, J.; Kimura, T.; Matsuda, T.; Yokoyama, T.; Fukiha, J.; et al. Acute exacerbations of fibrotic interstitial lung diseases. Respirpirology 2020, 25, 525–534. [CrossRef] [PubMed]
60. Richeldi, L.; du Bois, R.M.; Raghu, G.; Azuma, B.; Brown, K.K.; Costabel, U.; Cottin, V.; Flaherty, K.R.; Hansell, D.M.; Inoue, Y.; et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014, 370, 2071–2082. [CrossRef] [PubMed]
61. Fletcher, S.V.; Jones, M.G.; Renzoni, E.A.; Parfrey, H.; Hoyles, R.K.; Spinks, K.; Kokosi, M.; Kwok, A.; Warburton, C.; Tittmuss, V.; et al. Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice. Eur J Open Res. 2018, 4, 00049–00218. [CrossRef] [PubMed]

62. King, T.E., Jr.; Bradford, W.Z.; Castro-Bernardini, S.; Fagan, E.A.; Glaspole, I.; Glassberg, M.K.; Gorina, E.; Hopkins, P.M.; Kardatzke, D.; Lancaster, L.; et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014, 370, 2083–2092. [CrossRef] [PubMed]

63. Flaherty, K.R.; Wells, A.U.; Cottin, V.; Devaraj, A.; Walsh, S.L.F.; Inoue, Y.; Richeldi, L.; Kolb, M.; Tetzlaff, K.; Stowasser, S.; et al. Nintedanib in progressive fibrosing interstitial lung diseases. N. Engl. J. Med. 2019, 381, 1718–1727. [CrossRef] [PubMed]

64. Wells, A.U.; Flaherty, K.R.; Brown, K.K.; Inoue, Y.; Devaraj, A.; Richeldi, L.; Moua, T.; Crestani, B.; Wuyts, W.A.; Stowasser, S.; et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir. Med. 2020, 8, 453–460. [CrossRef]

65. Behr, J.; Prasse, A.; Kreuter, M.; Johow, J.; Rabe, K.F.; Bonella, F.; Bonnet, R.; Grohe, C.; Held, M.; Wilkens, H.; et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): A double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir. Med. 2021, 9, 476–486. [CrossRef]

66. Raghu, G.; Collard, H.R.; Egan, J.J.; Martinez, F.J.; Behr, J.; Brown, K.K.; Colby, T.V.; Cordier, J.F.; Flaherty, K.R.; Lasky, J.A.; et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011, 183, 788–824. [CrossRef]

67. Naccache, J.M.; Jouneau, S.; Didier, M.; Borie, R.; Cachanado, M.; Bourdin, A.; Reynaud-Gaubert, M.; Bonniaud, P.; Israël-Biet, D.; Prevot, G.; et al. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 2022, 10, 26–34. [CrossRef]

68. Chiu, Y.H.; Spierings, J.; de Jong, P.A.; Hoesein, F.M.; Grutters, J.C.; van Laar, J.M.; Voortman, M. Predictors for progressive fibrosis in patients with connective tissue disease associated interstitial lung diseases. Respir. Med. 2021, 187, 106579. [CrossRef]

69. Zamora-Legoff, J.A.; Krause, M.L.; Crowson, C.S.; Ryu, J.H.; Matteson, E.L. Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease. Clin. Rheumatol. 2016, 35, 2585–2589. [CrossRef] [PubMed]

70. Yamaguchi, K.; Yamaguchi, A.; Ita, M.; Onuki, Y.; Shin, Y.; Uno, S.; Hanazato, C.; Taguchi, K.; Umetsu, K.; Aikawa, M.; et al. Interstitial lung disease with myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis in elderly patients. Rheumatol. Int. 2021, 41, 1641–1650. [CrossRef]

71. Denning, D.W.; Cadranel, J.; Beigelman-Aubry, C.; Ader, F.; Chakrabarti, A.; Blot, S.; Ullmann, A.J.; Dimopoulos, G.; Lange, C. Chronic pulmonary aspergillosis: Rationale and clinical guidelines for diagnosis and management. Eur. Respir. J. 2016, 47, 45–68. [CrossRef] [PubMed]

72. Yamakawa, H.; Takayanagi, N.; Miyahara, Y.; Ishiguro, T.; Kanauchi, T.; Hoshi, T.; Yanagisawa, T.; Sugita, Y. Prognostic factors and radiographic outcomes of nontuberculous mycobacterial lung disease in rheumatoid arthritis. J. Rheumatol. 2013, 40, 1307–1315. [CrossRef] [PubMed]

73. Kurosaki, F.; Bando, M.; Nakayama, M.; Mato, N.; Nakaya, T.; Yamasawa, H.; Yoshimoto, T.; Fukushima, N.; Sugiyama, Y. Clinical features of pulmonary aspergillosis associated with interstitial pneumonia. Intern. Med. 2014, 53, 1299–1306. [CrossRef] [PubMed]

74. Odashima, K.; Kagiyma, N.; Kanauchi, T.; Ishiguro, T.; Takayanagi, N. Incidence and etiology of chronic pulmonary infections in patients with idiopathic pulmonary fibrosis. PLoS ONE 2020, 15, e0230746. [CrossRef] [PubMed]

75. Kawamura, K.; Ichikado, K.; Ichiyasu, H.; Anan, K.; Yasuda, Y.; Suga, M.; Sakagami, T. Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: Incidence and risk factors from real-world experience. BMC Pulm. Med. 2019, 19, 113. [CrossRef]

76. Sebastiani, M.; Manfredi, A.; Vacchi, C.; Cassone, G.; Faverio, P.; CavaZZa, A.; Sverzelli, N.; Salvareani, C.; Luppi, F. Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis. Clin. Exp. Rheumatol. 2020, 38 (Suppl. 124), 221–231.